Amgen, Inc. (AMGN) Stirs the Pot in the Cancer-Related Sector

Page 2 of 2

What it all boils down to

Basing your decision to buy a stock on speculation about possible takeovers is a recipe for disaster. While Pharmacyclics, Inc. (NASDAQ:PCYC)appears similar to Onyx, many variables could mean firms such as Amgen, Inc. (NASDAQ:AMGN) aren’t looking elsewhere for a possible deal. However, buying a company that is fundamentally strong will increase your chances of securing a winner that could be the subject of a buyout. This is how two of my former pharmaceutical picks ended up, and they were both bought at major premiums, netting me a tidy sum.


Phillip Woolgar has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

The article Amgen Stirs the Pot in the Cancer-Related Sector originally appeared on Fool.com.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2